Jazz Pharmaceuticals: 60% Price Potential from Record Revenue and Success in Patent Dispute

The stock of Jazz remains highly interesting. In November 2024, I reported about the company's potentials, one of which is Zepzelca, an already approved medication that has the potential to become the new standard therapy for an aggressive form of lung cancer. Jazz presented promising new study results for both Zepzelca and Xywav, the only approved medication of its kind in the USA for the treatment of sleep disorders, in October. Based on the figures for 2024 and a legal victory gained, signs are increasingly pointing towards significant price...